SCHEDULE: Wellington Management Discloses Immunocore Stake

Wellington Management Group LLP and its affiliates have reported a significant beneficial ownership stake in Immunocore Holdings plc, holding 11.6% of the common stock as of June 30, 2026.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, have filed a Schedule 13G.
• This filing indicates their beneficial ownership of Immunocore Holdings plc's common stock.
• As of June 30, 2026, the aggregate beneficial ownership is reported as 5,959,773 shares, representing 11.6% of the class.
• The filing is an amendment (Amendment No. 6) to a previous Schedule 13G.
• The reporting entities are classified as investment advisers (IA) or holding companies (HC).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership rather than a reflection of company performance or strategy.

Positives

• Significant institutional investor interest from a major asset manager like Wellington Management.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The filing itself does not contain performance data or strategic updates, making it difficult to assess direct impact.
• The aggregate beneficial ownership percentage is 11.6%, which, while substantial, does not indicate control.

Risks

• Potential for future changes in Wellington Management's stake, which could impact share price.
• The filing does not provide insight into the investment strategy or rationale behind holding this stake.

Future Outlook

This filing does not contain forward-looking statements or guidance from Immunocore Holdings plc. It solely pertains to the ownership disclosure by Wellington Management.

Industry Context

StockSavvy.ai notes that large asset managers like Wellington Management frequently file Schedule 13G forms to disclose significant beneficial ownership stakes in publicly traded companies. This is a standard regulatory requirement and indicates sustained interest from institutional investors in the biotechnology sector, where Immunocore operates.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder, potentially influencing market perception.
• Management: Awareness of substantial ownership by a major asset manager.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Wellington Management for any changes in their beneficial ownership of Immunocore Holdings plc.
• Observe Immunocore Holdings plc's own SEC filings for company-specific performance and strategic updates.

Key Dates

Keywords

Immunocore Holdings plc, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor